On occassion, we've compared Esperion to Resverlogix....sometimes fairly and sometimes unfairly. I've been a regular follower of Esperion for a few years now. Although we can't directly compare the two companies, one thing with Esperion that I've appreciated is their investor communications (webcasts, twitter presence, blog, etc.).

Esperion maintains a Hearts and Minds blog. It has a good mix of blog posts from not just the CEO Tim Mayleben, but also their Chief Medical Officer, Senior Vice President of Strategic Marketing and Product Planning, Executive Director of Advocacy & Professional Relations and even a guest blog by Antonio M. Gotto, Jr., MD.

Wouldn't it be great if we had regular blog entries from Dr. Norman Wong, Dr. Ewelina Kulikowski, Dr. Michael Sweeney, Don McCaffrey and other members of the Resverlogix team? Even guest blogs from members of the BETonMACE or Renal Clinical Steering Committees. Summaries of the latest of greatest from conferences, opinions on recent clinical trials and how they relate to the prospects of product(s) in the Resverlogix pipeline, insights on epigenetics research especially that on BET bromodomains, posts that remind people that apabetalone is distinct from CETP inhibitors, etc. 

I know Resverlogix has smart people on board. We've heard them present and speak before. I sure hope that in the new website rollout, that they consider adding regular promotional/educational blog entries.

Growacet wrote "But I'm thinking the so called "Cone of Silence" may be lifting slowly.....and that the company is finally going to be moving into a time of increased communication and dare I say, promotion." I sure hope you're right.  

BearDownAZ